InvestorsHub Logo
Post# of 252758
Next 10
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: poorgradstudent post# 40961

Monday, 01/22/2007 9:27:36 PM

Monday, January 22, 2007 9:27:36 PM

Post# of 252758
I like Pharmion (a lot actually) I just have given up hope of getting it under 20 any time soon (and if that were to happen now it would likely be because of something so unfavorable I would lower my target). I actually think Thalidomide (European sales) will at least remain solid (if not grow for some time), I buy Mahaffys arguments on it anyway. I also like the potential for the Methylgene compound they licensed a while back. What is waying against my liking them more is:
1-The nearly double in price since I was close to purchasing (granted they have had good news since so I should pay more)
2-Their two main revenue sources have pretty significant competion (Revlmid-2 fronts, Velcade, etc.)
3-While I think Vidaza and Thalidomide could hold up I think the market will get nervous pretty easily on either dropping (I thought that might give me a buying Opportunity).

I am not a big Mahaffy fan but will admit he (sounds) a lot better then Dr. Raj anyway. I think he paid a lot for both the Methylgene compound and Satraplatin but he may look good in the end.

My reasoning for SPPI (at current levels) over PHRM (at current levels) is:
10% royalty could possibly generate $50 million in a couple years (I think easily and wouldn't be suprised to see a lot more uses for an Oral Platinum drug pushing sales much higher). With their current burn that could give them .50 - .75 EPS.
In the meantime you get the milestones from GPC and should they get lucky in a settlement with GPC that could be very significant for SPPI.
Then longer term they have a couple of shots on goal with their Bladder cancer compound and the drug for prostate cancer/benign prostatic hypertrophy. The fact that Dr. Raj does small deals makes me less nervous too (but I don't like all the Options/Warrants sitting out there).

I think Pharmion will be putting a lot of money into R&D for the next couple years anyway so people may go through a period where they don't know whether to value it on revenue or pipeline potential. But I still keep watching it for an opportunity.

I appreciate your insights poorgradstudent and would be interested in any of your thoughts on Pharmion/Satraplatin
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.